How new technology can impact cardiac imaging in oncology clinical trials and have broader implications for patient safety.
The reality of risk-based monitoring: history and successful implementation for late phase research.
Sponsor-driven, CRO/recruitment provider collaborations propel cost-efficient study completion.
Health technology assessment is a field of analysis that evaluates the medical, social, ethical, and economic implications of development, diffusion, and use of health technology.
Study results using a quality-by-design method, risk-based monitoring, and real-time direct data entry.
One of the many activities across the clinical development cycle that is non-negotiable is the creation, collection, management, and storage of the documents that are contained in the Trial Master File.
An effective clinical trial is one of the most crucial stages in the creation of a new drug.
The use of RBM may be the only way forward as long as the development of medicines relies on clinical testing.
Clinical research organizations should look to peer-to-peer mentoring for professional development.
Study results using a quality-by-design method, risk-based monitoring, and real-time direct data entry.
IntroductionAfter decades of promise, we have begun to realize the fruit of “-omics” technology. Recent advances in proteomics, genomics and metabolomics have enabled us to understand the molecular basis of disease at both the diagnostic and treatment levels. Equally important, a growing suite of biomarkers now provides predictive value for diagnosis, disease progression and cure/remission.
Differing levels of trust in clinical trials information channels across diverse populations is examined in this research.
One of the many activities across the clinical development cycle that is non-negotiable is the creation, collection, management, and storage of the documents that are contained in the Trial Master File.
A view on redefining key roles across the evolving clinical development landscape.
How one biotech is tackling the unmet need for additional immunotherapies and combination approaches in cancer.
Study results using a quality-by-design method, risk-based monitoring, and real-time direct data entry.
Clinical trials today are more commonly assessing quality of life and other PRO measures as part of post-approval studies to present evidence on treatment effectiveness. It is crucial, therefore, that clinical teams have a strong plan for the capture and analysis of PROs data, and the resources required to draw clinically meaningful extrapolations.
The four essential steps to ensuring optimal clinical deliverable specifications and process controls.
The reality of risk-based monitoring: history and successful implementation for late phase research.
In this Q&A, David Esposito, CEO of ONL Therapeutics provides a glimpse into the company's mission, challenges, and strategies associated with clinical trials.
Conducting Large Simple Trials to answer questions about "real-world" medical interventions is not a recent concept.
Constant technological advancements continue to alter the compliance battle.
Increasing development costs and high failure rates require earlier integration of imaging data in the Phase I setting.
No matter how long you?ve been in the clinical trials business, the mantra is always the same: not enough investigators, not enough patients, enrollment falling behind, need for rescue sites, study budget overspend.
The pharmaceutical industry continues to outsource more clinical trials to contract research organizations each year...
Strong working relationships between clinical trials sites and the CRO managing the study are critical to successfully executing a clinical trial.